ESMO 2025 preview – a bemarituzumab reckoning approaches
Meanwhile, Astra, Merck and Novartis look for new Enhertu, Keytruda and Pluvicto additions.
Alentis doubles down on Claudin1
ALE.P03 is the biotech's third anti-Claudin1, and its second ADC.
HengRui presses on in HER3, despite Merck’s failure
The Chinese group will soon start a pivotal trial of its ADC ruza-can in first-line NSCLC.
Joyo starts its first pivotal trial
While InxMed, Takara and L&L have phase 3 plans in lung cancer and beyond.
Roche pushes a novel myeloma target
The company will be the first to take a FcRH5-targeting project into phase 3.
What now for NK-cell engagers?
Big pharma interest remains, but the mood is fast turning gloomy.
In triple-negative pumitamig concedes PD-L1-high disease
The Rosetta Breast-01 phase 3 trial will only evaluate patients with low PD-L1 expression.
Lilly moves to overtake Relay
A phase 3 trial of the Scorpion-originated tersolisib will be in first-line breast cancer.
Daiichi makes its sting move
The recently unveiled conjugate DS3610a is to start phase 1.
